Kamada Wins FDA Approval for Glassia - a New Liquid, Ready-to-Use Treatment for Alpha-1 Antitrypsin Deficiency
Links shared publicly online about this topic.
- 1,040total visits
Kamada Wins FDA Approval for Glassia - a New Liquid, Ready-to-Use Treatment for Alpha-1 Antitrypsin Deficiency
Glassia (alpha1-proteinase inhibitor (human)) is used to treat Alpha 1 deficiency. Includes Glassia side effects, interactions and indications.
View full resource at drugs.com
Tags: FDA
Most Recently Shared on July 7, 2010 at 11:53 am By:
FDA Approves Glassia - a New Liquid, Ready-to-Use Treatment for Alpha-1 Antitrypsin Deficiency - http://bit.ly/bpOUdG (via @drugscom)
Also Shared By:
Advertisement
Drugs.com
@Drugscom
FDA Approves Glassia - a New Liquid, Ready-to-Use Treatment for Alpha-1 Antitrypsin Deficiency - http://bit.ly/bpOUdG
1 year ago...